Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Executive Summary

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Advertisement

Related Content

Venture Funding Deals: Orchard Brings Total To $291m
Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Gritstone Grabs $92.7m To Test Personalized Vaccines In Humans
VC Roundup: More Funds Raise Cash For Biotech; Morphic Closes $51.5m Series A
AZ Spins Out Entasis To Tackle Resistant Infections
Biocon launches anti-CD-6 psoriasis biologic in India
BMS finalises Amylin buy, Lilly cashes in too

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel